LitCoin-sentences  

PubMed:26684240 JSONTXT 28 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-90 Sentence denotes Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
T2 91-285 Sentence denotes Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still insufficiently understood, and the genetic alterations associated with drug responses have not been studied.
T3 286-560 Sentence denotes Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).
T4 561-642 Sentence denotes The mean numbers of somatic mutations in each case varied widely from 20 to 4682.
T5 643-865 Sentence denotes Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
T6 866-972 Sentence denotes TP53 was recurrently mutated in three cases, whereas CNBD1 and RB1 mutations were identified in two cases.
T7 973-1167 Sentence denotes Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
T8 1168-1482 Sentence denotes We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
T9 1483-1537 Sentence denotes All tumor specimens were obtained before chemotherapy.
T10 1538-1699 Sentence denotes In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.